Wednesday, January 27, 2010

Abbott's Niaspan® Sales Jump 15% -- On Study Win Vs. Merck's Zetia®

No surprise here -- per press clippings of Abbott's Q4 2009 results release:

. . . .Sales of [all Abbott] prescription drugs rose 5.2 percent to $4.85 billion. Global Humira® sales rose 23 percent to $1.66 billion, making it by far the company's biggest product. Sales of Niaspan®, a treatment to raise "good" HDL cholesterol, jumped 15 percent to $254 million, helped by a recent study in which the drug it reduced clogging in neck arteries better than Merck & Co.'s Zetia®. . . .

Also mentioned above is Humira® -- Abbott's biggest seller -- remember, it has a partially shared-history with New Merck, too.


Anonymous said...

I'm really happy for Abbott ... they're obviously a company of great integrity. I was actually on niaspan once ... a new doc of mine gave it to me. Unfortunately, it caused me to have a few stomach issues. I think if I would have stuck it out, it would have made a real difference. I wasn't very patient at that time in my life.

Thanks for your great column. As usual, it's quite informative.

Condor said...

Thanks for stopping by!

Do check back in, from time to time.